Dr. Andy Minn is the Chair of the Immuno-Oncology Program and an Attending in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center (MSK). He is also Director of the Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation. He received his MD and PhD from the University of Chicago and finished his residency in radiation oncology along with his post-doctoral training at MSK. His research seeks to understand key mechanisms of cancer immunotherapy resistance. Specifically, his work focuses on the role of chronic interferon and inflammatory signaling, which are pathways that are typically activated when normal cells become persistently infected with a virus. Surprisingly, cancers and many cancer therapies also can activate these pathways, prompting an interest in understanding how this happens, the impact on anti-tumor immunity, and its clinical significance. An overarching goal is to translate this understanding to better inform the design of clinical trials. Dr. Minn's work has been published in prestigious scientific journals such as Cell, Science, Nature, and Immunity. He is also a member of the American Society for Clinical Investigators (ASCI).